Many promising therapeutic modalities have limited clinical efficacy due to the challenges of delivering molecules into cells. SQZ Biotech seeks to address this fundamental problem by developing its CellSqueeze platform for use in drug discovery and clinical applications. SQZ\'s technology seeks to overcome longstanding barriers in the field by facilitating more effective access to the intracellular space. Through internal research programs and external partnerships, SQZ is leading a revolution in scientists\' approach to disease research and clinical therapies, developing novel methods to engineer cell function and harness the power of a patient\'s own cells to combat disease more effectively across a broad range of indications.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/24/15 | $5,000,000 | Series A |
Polaris Partners | undisclosed |
| 09/30/16 | $16,000,000 | Series B |
NanoDimension Polaris Partners | undisclosed |
| 12/02/16 | $4,000,000 | Series B |
Quark Venture | undisclosed |
| 12/05/17 | undisclosed | |||
| 08/08/18 | $72,000,000 | Series C |
Bridger Healthcare Partners Global Health Science Fund Illumina Ventures Invus JDRF T1D Fund NanoDimension Orient Life Polaris Partners Viva Ventures Biotech Group | undisclosed |
| 05/18/20 | $65,000,000 | Series D |
GV Illumina Ventures Invus JDRF T1D Fund NanoDimension Polaris Partners Temasek  | undisclosed |
